Biology Reference
In-Depth Information
120. Willenbrock H et al (2009) Quantitative miRNA expression analysis: comparing microarrays
with next-generation sequencing. RNA 15(11):2028-2034
121. Mi S et al (2007) MicroRNA expression signatures accurately discriminate acute lymphoblas-
tic leukemia from acute myeloid leukemia. Proc Natl Acad Sci USA 104(50):19971-19976
122. Fulci V et al (2009) Characterization of B- and T-lineage acute lymphoblastic leukemia by
integrated analysis of MicroRNA and mRNA expression profiles. Genes Chromosomes
Cancer 48(12):1069-1082
123. Dyrskjot L et al (2009) Genomic profiling of microRNAs in bladder cancer: miR-129 is
associated with poor outcome and promotes cell death in vitro. Cancer Res
69(11):4851-4860
124. Schepeler T et al (2008) Diagnostic and prognostic microRNAs in stage II colon cancer.
Cancer Res 68(15):6416-6424
125. Lebanony D et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes
squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 27(12):
2030-2037
126. Ueda T et al (2010) Relation between microRNA expression and progression and prognosis
of gastric cancer: a microRNA expression analysis. Lancet Oncol 11(2):136-146
127. Guan Y et al (2010) MiRNA-196 is upregulated in glioblastoma but not in anaplastic astro-
cytoma and has prognostic significance. Clin Cancer Res 16(16):4289-4297
128. Ji J et al (2009) MicroRNA expression, survival, and response to interferon in liver cancer. N
Engl J Med 361(15):1437-1447
129. Navarro A et al (2009) Regulation of JAK2 by miR-135a: prognostic impact in classic
Hodgkin lymphoma. Blood 114(14):2945-2951
130. Yu SL et al (2008) MicroRNA signature predicts survival and relapse in lung cancer. Cancer
Cell 13(1):48-57
131. Eitan R et al (2009) Tumor microRNA expression patterns associated with resistance to plati-
num based chemotherapy and survival in ovarian cancer patients. Gynecol Oncol
114(2):253-259
132. Hwang JH et al (2010) Identification of microRNA-21 as a biomarker for chemoresistance
and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One
5(5):e10630
133. Giovannetti E et al (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical out-
come and pharmacologic aspects underlying its role in the modulation of gemcitabine activ-
ity. Cancer Res 70(11):4528-4538
134. Gong C et al (2011) Up-regulation of miR-21 mediates resistance to trastuzumab therapy for
breast cancer. J Biol Chem 286(21):19127-19137
135. Ferracin M et al (2010) MicroRNAs involvement in fludarabine refractory chronic lympho-
cytic leukemia. Mol Cancer 9:123
136. Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med
352(8):804-815
137. Rossi S et al (2010) microRNA fingerprinting of CLL patients with chromosome 17p deletion
identify a miR-21 score that stratifies early survival. Blood 116(6):945-952
138. Visone R et al (2009) Karyotype-specific microRNA signature in chronic lymphocytic leuke-
mia. Blood 114(18):3872-3879
139. Stamatopoulos B et al (2009) microRNA-29c and microRNA-223 down-regulation has
in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification.
Blood 113(21):5237-5245
140. Sørensen KD, Ørntoft TF (2010) Discovery of prostate cancer biomarkers by microarray
gene expression profiling. Expert Rev Mol Diagn 10(1):49-64
141. Porkka KP et al (2007) MicroRNA expression profiling in prostate cancer. Cancer Res
67(13):6130-6135
142. Ozen M et al (2008) Widespread deregulation of microRNA expression in human prostate
cancer. Oncogene 27(12):1788-1793
143. Ambs S et al (2008) Genomic profiling of microRNA and messenger RNA reveals deregu-
lated microRNA expression in prostate cancer. Cancer Res 68(15):6162-6170
Search WWH ::
Custom Search